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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not using the 
LigaSure device provides any benefit in morality in patients undergoing hepatic resection 
surgery. 
 
STUDY DESIGN: Review of three English language randomized control trials published in 2007, 
2009 and 2012.  
 
DATA SOURCES: Data sources obtained for this review primary studies published in peer-
reviewed journals, found using PubMed.  
 
OUTCOMES MEASURED: Patient mortality, defined as death within 30 days of the surgical 
procedure. 
 
RESULTS: The study done by Doklestic and et al had 3 patient mortalities occur. The deaths 
occurred on post op days three, four and nine and were due to pulmonary embolism, acute 
myocardial infarction and heart failure, respectively.8 Zero mortalities occurred in the 
remaining two studies.9,10 
 
CONCLUSIONS: The results of the studies showed that LigaSure did not provide a benefit in 
mortality compared to the clamp crushing method, the cavitron ultrasonic surgical aspirator 
(CUSA) method and to ultrasonic shears.  
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INTRODUCTION 
Liver cancer is the sixth most common cancer worldwide.1 For the year 2018, it was 
estimated that 42,220 adults in the United States would be diagnosed with primary liver cancer. 
It was also predicted that 30,200 deaths would occur in 2018 due to liver cancer, with about 
68% of these deaths being men and 32% being women.2 Since 1980, the incidence of liver 
cancer has tripled.2 From 2010-2011, the number of hospitalizations for liver cancer was 
44,071.3 Based on these statistics, it is inevitable that a physician assistant or other health care 
provider will encounter a patient with liver disease, no matter the subspecialty. The median 
cost of hospitalization for liver resection surgery has more than doubled in the 10 years from 
1997 to 2007—from $23,856 to $50,758.4 These numbers do not take into account the 
additional follow up visits, costs of the diagnostic imaging studies performed prior to the 
surgery or the cost of other adjunctive treatments if used.  The most common etiology of 
primary liver cancer is hepatocellular carcinoma (HCC).5 HCC, cholangiocarcinoma and 
metastatic disease are among the most common causes of malignant hepatic tumor.5 In 
reference to benign liver tumors, hemangiomas are the most common type, occurring in about 
1-5% of adults. 6 Additional common types include adenomas and focal nodular hyperplasia.5  
Risk factors for solid liver tumors include smoking, using oral contraceptive pills, 
parasitic infections, anabolic steroid use, and non-alcoholic fatty liver disease.5 When talking 
about HCC specifically, risk factors include alcohol abuse, obesity, cirrhosis, type II diabetes, and 
chronic viral hepatitis. 5 Regardless of the specific disease diagnosed, solid liver tumor disease 
presents with similar symptoms across all patients. Patient symptoms may include localized 
abdominal pain, weight loss, early satiety, jaundice, palpable abdominal masses, or ascites.5 It is 
a possibility that patients will be asympotmatic.5 During a workup of solid liver tumor diseases, 
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laboratory blood work needs to be checked. Elevations in laboratory results such as serum 
alpha-fetoprotein levels, liver function tests including ALT, AST and ALP levels, and bilirubin 
levels support. But do not confirm, a diagnosis of a solid liver tumor.5 Prolonged PT time may be 
seen as well.5 One of the first diagnostic imaging studies performed when a liver tumor is on 
the differential diagnosis is an abdominal ultrasound. However, the diagnostic test of choice for 
solid liver tumors is an abdominal CT with contrast.5 Alternatively an MRI can be done.5  Fine 
needle biopsies can be used in order to confirm a diagnosis that was unclear from the 
laboratory tests imaging studies.5 The treatment for liver tumors depend on the disease type 
and its extent. For example, liver disease that has not spread past the liver or invaded the blood 
stream, have surgery as a potential treatment option.7 Whereas, metastatic liver disease may 
not qualify for surgical treatment.7 Procedural treatment options that do not remove portions 
of the liver include trans-arterial embolization, radiofrequency ablation, and 
radioembolization.7 These three treatments directly destroy the tumor by either disrupting its 
blood supply or by using high frequency electricity to kill the cells.7 Surgical removal treatment 
options for liver tumors include hepatic resection of the affected portion or liver 
transplantation in severely damaged livers. 
Liver resection has been shown to be a curative treatment for patients with some 
benign and malignant liver tumors.5 One of the traditional techniques used is known as the 
clamp crushing method, where the liver parenchyma is crushed by a small Kelly clamp.8 The 
clamp crushing method is considered the gold standard for surgical resection.8 Another popular 
technique is the Cavitron Ultrasonic Surgical Aspirator (CUSA). This technique uses ultrasonic 
vibration to break down the parenchyma while simultaneously irrigating and aspirating the 
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field.8 The ultrasonic shears also use vibration, as well as pressure, to denature proteins in the 
parenchyma and collapse the vessels.9 The LigaSure vessel sealing system uses energy and 
pressure to fuse the vessels in the liver parenchyma.9 The LigaSure vessel sealing system is 
being proposed to evaluate if there is a more effective and less fatal technique for hepatic 
resections in patients with hepatic tumors. This review evaluates three randomized control 
trials comparing LigaSure to other current resection techniques.   
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not using the LigaSure 
device provides any benefit in mortality patients undergoing hepatic resection surgery. The 
hypothesis about the objective is that LigaSure provides more benefit in mortality than the 
comparative surgical methods in adults undergoing hepatic resection. 
METHODS 
Three randomized control trials were selected to create this evidence based medicine 
(EBM) review8–10.  The population studied in these trials included adult patients who 
undergoing hepatic resection surgery. The intervention in each study was the LigaSure vessel 
sealing system. The study conducted by Campagnacci and et al compared LigaSure to ultrasonic 
shears.9 In the study done by Doklestic and et al, compared LigaSure to the clamp crushing 
method as well as to the cavitron ultrasonic surgical aspirator.8 The final study conducted by 
Ikeda and et al compared LigaSure to the clamp crushing method.10 This EBM review focuses on 
one specific outcome, patient mortality. The studies observed if any mortalities occurred and if 
LigaSure provided a benefit in mortality compared to the comparison methods listed 
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previously, depending on the study. Mortality was defined as death within 30 days of the 
surgical procedure.  
The three randomized control trials were selected via PubMed databases by using four 
keywords; “LigaSure”, “hepatic”, “liver”, and “resection”. Each study was published in peer-
reviewed journals and in English. These specific articles were selected based on their relevance 
to the clinical question being addressed and if the outcomes measured were patient-oriented 
evidence that matters (POEMs). Inclusion criteria consisted of the articles being randomized 
control trials, published after the year 2007 and that the patients were adults over the age of 
18. The only exclusion criteria for this review was that the patient population could not consist 
of children, under the age of 18. Table 1 displays the demographics and characteristics of each 
randomized control trial selected for this EBM review. P-values were used as a statistic in each 
study as well as an additional statistic for continuous data. The statistic used in the study 
conducted by Campagnacci and et al was the unpaired student t-test.9 In the study done by 
Doklestic and et al, two statistics were used; ANOVA and Kruskal-Wallis.8 The Wilcoxon rank 
sum test was the statistic used in the study done by Ikeda and et all.10  
Table 1: Demographics & characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion criteria Exclusion 
criteria 
W/D Intervention
s 
Camp-
agnacci 
(2007)2 
RCT 24 39-81 All eligible hepatic 
resection patients 
enrolled during a 
21 month period 
Cirrhosis, 
Child-Pough 
B-C 
classification, 
pre-operative 
concrete 
suspicion of 
extrahepatic 
disease or 
multiple 
0 EBVS 
LigaSure vs. 
ultrasonic 
shears for 
hepatic 
resections 
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hepatic 
disease that is 
not 
amendable to 
complete 
curative 
resection, ASA 
greater than 
stage III 
Dokles-
tic 
(2012)8 
RCT 60 Avg 
age: 
57.88 
+  
SD 
(15.83) 
Hepatectomy for 
benign and 
malignant liver 
tumors in patients 
with adequate 
functional reserve 
of the heart, lungs 
and kidneys. 
Cirrhosis 0 LigaSure vs. 
clamp crush 
technique 
vs. CUSA for 
liver 
resection 
Ikeda 
(2009)1
0 
RCT 120 20-85 Patients 20-85 y.o.  
scheduled to 
undergo hepatic 
resection of some 
benign or 
malignant 
hepatobiliary 
disease and 
acceptable 
coagulation 
profile (platelet 
count > 5 x 104/ul, 
prothrombin time 
activity > 50%, 
bleeding time < 5 
minutes 
Other 
malignant 
diseases, bilio-
enteric 
reconstructio
n cases, 
impossibility 
of inflow 
occlusion, and 
living donors 
of grafts for 
liver 
transplantatio
n 
0 Vessel 
sealing 
system 
LigaSure vs. 
clamp 
crushing 
method for 
liver 
transection 
 
OUTCOMES MEASURED 
 For this EBM review, the primary outcome measured was mortality of the patient.  
Mortality was defined as death of the patient within 30 days of the hepatic resection surgical 
procedure.  
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RESULTS 
For this EBM review, three randomized control trials that compared the LigaSure vessel 
sealing system to various different dissection techniques for adult patients undergoing hepatic 
resection surgeries were analyzed. Table 2 displays the mortality results organized by each 
study and the dissection technique used.  
Table 2: Patient mortalities compared by study and by resection technique 
 LigaSure Clamp Crushing CUSA Ultrasonic shear 
Campagnacci9 0 - - 0 
Doklestic8 1 2 0 - 
Ideka10 0 0 - - 
 
In the study done by Doklestic and et al, the patients were selected from an emergency 
surgery clinic in Serbia.8 Sixty patients with hepatic tumors that were undergoing liver resection 
surgery from November 2008 to August 2010 were selected for the study.8 Patients were 
excluded if they had been diagnosed with cirrhosis and included “liver tumors in patients with 
adequate functional reserve of the heart, lungs and kidney.”8 Thirty-nine patients in this study 
had malignant liver tumors due to metastatic colorectal carcinoma, HCC, gallbladder carcinoma, 
and cholangiocarcinoma.8 The remaining 21 patients had benign liver disease such as 
hemangiomas, adenomas, focal nodular hyperplasia, simplex cysts and echinococcal cysts.8 
Three different resection techniques were compared, LigaSure, CUSA and the clamp crushing 
method. Each technique group consisted of 20 randomized patients.8 The surgeries for each 
group were performed by a single operating team and were kept blinded to the patients group 
assignments until they were in the operating room.8 The total mortality was 5%.8 There were no 
mortalities in the group of patient that received the CUSA technique.8 Two of the three deaths 
in this study occurred in the group of patient that received the clamp crushing method. Both 
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deaths were due to surgical complications. One patient died from a pulmonary embolism and 
the other died from an acute myocardial infarction.8 The third and final death in the study 
occurred in the LigaSure group. The patient in this group who died “had a malignant cardiac 
arrhythmia disorder and heart failure with previous history of cardiac disease”.8 The p-value for 
mortality in this study was >0.05.8 A p-value of <0.05 was needed to be considered statistically 
significant.8 
The study conducted by Campagnacci and et al was comprised of 24 patients 
undergoing hepatic resection for malignant or benign lesions, during a 21 month period.9 
Patients were excluded if they had cirrhosis, Child-Pough B-C classification, pre-operative 
concrete suspicion of extrahepatic disease or multiple hepatic disease that was not amenable 
to complete curative resection, and American Society of Anesthesiologists (ASA) physical status 
classification greater than stage III.9 Twenty-one of the eligible patients had malignant liver 
tumors form either HCC or metastatic colorectal carcinoma.9 The remaining three patients had 
benign liver tumors from hemangiomas or intrahepatic lithiasis.9 All patients completed the 
study and were randomized into the LigaSure group or into the ultrasonic shears harmonic 
scalpel.9 Each of the resection surgeries were performed by a surgical team who had previously 
conducted at least 50 hepatectomies, as well as supervised by two expert surgeons.9 The two 
expert surgeons were blinded to the group assignments up until the day of the surgery.9 There 
was no mortality recorded for either group, see Table 2. No further statistics were given for 
mortality.9  
In the study performed by Ikeda and et al, there were 165 patients who were 
undergoing hepatic resection surgery, at the Tokyo University Hospital, for benign or malignant 
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hepatobiliary disease.10 Of those 165, 120 qualified and all completed the study.10 A majority of 
the 45 patients were excluded for one of the following reasons; high risk of hemorrhage, 
required an additional surgical procedure, unable to undergo inflow occlusion or refusal to 
participate.  All 120 patients had malignancy in the form of either primary or metastatic liver 
carcinoma.10 Half of the patients were randomized into the LigaSure vessel sealing group while 
the other half were randomized into the clamp crushing group.10 The results of these group 
placements were not blinded to the surgical team.10 Each surgery was performed by three 
consultants and three trainees.10 No mortalities in either group occurred which is shown in 
Table 2. 10 The p-value was considered statistically significant at <0.05 with a 95% confidence 
interval.10 There was no p-value for mortality calculated due to the fact that it did not occur.  
DISCUSSION 
The three randomized control trials reviewed, showed that the LigaSure vessel sealing 
system, in comparison to other resection techniques, did not provide a benefit in mortality. In 
fact, each technique provided similar mortality outcomes across all studies. In the United 
States, about 44 million people have no health insurance, and another 38 million have 
inadequate health insurance.11 Surgical procedures and hospital stays are costly even for those 
with insurance coverage. Patients with hepatic tumors may not be able to afford hepatic 
resection surgeries or be able to obtain follow up care.  With the LigaSure instrument, there is 
an additional fifty dollar fee charged for each disposable hand piece used during the 
operation.10 When compared to the Kelly clamp, the cost is increased and provides no added 
benefit. The study performed by Doklestic and et al, mentions that a cost analysis of the devices 
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was not included.8 Future studies can address this limitation and perform this analysis to 
strengthen their results. 
The most common indication for hepatic resection surgery is a malignant tumor, often 
being HCC.12 However, patients with intermediate HCC, advanced HCC or HCC with portal 
hypertension, are not recommend to receive hepatic resection as a first line therapy due to a 
higher risk of mortality.13 The studies were limited in regards to blinding. Two of the three 
articles expressed how the surgeon and surgical team were blinded up until the day of the 
surgery.8,9 The additional article stated that no blinding had occurred.10 In the study done by 
Campagnacci and et al, based on their calculations, a sample size of 34 patients was needed to 
be statistically large enough.9 This study contained only 24 patients.9 The study performed by 
Ikeda and et al, containing 120 patients, stated that a sample size of 108 patients was needed 
to be statistically significant.10  In the study conducted by Doklestic and et al there was no 
statement made in regards to an appropriate sample size.8 Another limitation in this study was 
that there was no long term follow up or focus on the long term outcomes.8 
CONCLUSION 
 As surgical technology advances, surgical procedures must progress just as quickly. The 
studies provided in this EBM review failed to prove that there was benefit in mortality with the 
LigaSure vessel sealing system, when compared to other resection techniques. It is understood 
that each surgery cannot be identical. Factors such as patient’s comorbid conditions, surgeon 
experience and skill level, and access to certain surgical devices can impact the results of the 
surgery. 
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Future study is warranted to determine whether the LigaSure technique provides 
benefit in patient mortality. Aside from providing a cost analysis, these studies could try to 
reduce the discrepancies by setting stricter inclusion criteria. Even though this might reduce the 
sample size, having patients with similar medical histories and co-morbid conditions could 
strengthen the results. Since the incidence rates of liver tumor continue to increase, this 
treatment technique should continue to be studied.
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